| Rank | Ticker | Country | Price | Revenue | Analyst Rating | Analysts | IPO Year |
|---|---|---|---|---|---|---|---|
#1 | AVAH | United States | $6.28 | $2,433,199,000.00 | Buy | 9 | 2021 |
#2 | ANGI | United States | $6.48 | $736,386,000.00 | Buy | 7 | 2017 |
#3 | CDE | United States | $17.08 | $709,598,000.00 | Strong Buy | 5 | 1994 |
#4 | PD | United States | $6.01 | $492,546,000.00 | Buy | 9 | 2019 |
#5 | FIVN | United States | $14.43 | $1,149,088,000.00 | Buy | 19 | 2014 |
#6 | VRRM | United States | $13.87 | $132,969,000.00 | Buy | 5 | 2016 |
#7 | XHR | United States | $14.63 | $1,078,500,000.00 | Buy | 6 | 2014 |
#8 | TBPH | United States | $15.09 | $15,386,000.00 | Buy | 6 | 2013 |
#9 | ORN | United States | $10.88 | $852,260,000.00 | Strong Buy | 4 | 2007 |
#10 | LEVI | United States | $18.24 | $6,282,000,000.00 | Strong Buy | 13 | 2019 |
#11 | CXDO | United States | $6.16 | $68,167,000.00 | Strong Buy | 4 | 1999 |
#12 | ABEO | United States | $4.29 | $2,998,000.00 | Strong Buy | 4 | 2005 |
#13 | AMRX | United States | $11.87 | $0.00 | Strong Buy | 4 | 2018 |
#14 | LC | United States | $13.87 | $314,702,000.00 | Buy | 6 | 2008 |
#15 | CYRX | United States | $7.82 | $176,177,000.00 | Strong Buy | 9 | 2008 |
#16 | NTST | United States | $18.65 | $195,006,000.00 | Strong Buy | 13 | 2020 |
#17 | KROS | United States | $10.61 | $243,864,000.00 | Buy | 8 | 2020 |
#18 | YEXT | United States | $3.96 | $170,201,000.00 | Buy | 4 | 2017 |
#19 | GDYN | United States | $5.52 | $111,283,000.00 | Strong Buy | 6 | 2018 |
#20 | RUN | United States | $12.62 | $858,578,000.00 | Buy | 20 | 2015 |
#21 | APLS | United States | $16.98 | $1,003,782,000.00 | Buy | 21 | 2015 |
#22 | ALHC | United States | $16.60 | $3,948,719,000.00 | Buy | 10 | 2021 |
#23 | CRNC | United States | $6.06 | $251,781,000.00 | Buy | 4 | 2019 |
#24 | CERT | United States | $5.76 | $418,838,000.00 | Buy | 10 | 2020 |
#25 | MBLY | Israel | $6.71 | $1,894,000,000.00 | Buy | 19 | 2022 |
#26 | QUBT | United States | $6.68 | $682,000.00 | Strong Buy | 5 | 2019 |
#27 | LXEO | United States | $5.46 | $654,000.00 | Strong Buy | 10 | 2023 |
#28 | AVTX | United States | $13.89 | $27,813,137.00 | Strong Buy | 6 | 2015 |
#29 | SHC | United States | $13.15 | $1,163,617,000.00 | Buy | 7 | 2020 |
#30 | COMP | United States | $7.10 | $6,961,600,000.00 | Strong Buy | 11 | 2021 |
#31 | ADPT | United States | $12.42 | $276,976,000.00 | Strong Buy | 9 | 2019 |
#32 | ZETA | United States | $14.54 | $1,304,668,000.00 | Strong Buy | 11 | 2021 |
#33 | ARRY | United States | $7.33 | $1,284,141,000.00 | Buy | 19 | 2020 |
#34 | AZTA | United States | $19.91 | $593,821,000.00 | Strong Buy | 5 | 1996 |
#35 | ARVN | United States | $10.10 | $262,600,000.00 | Buy | 20 | 2018 |
#36 | BLZE | United States | $3.40 | $145,835,000.00 | Buy | 6 | 2021 |
#37 | UNCY | United States | $6.39 | $675,000.00 | Strong Buy | 4 | 2021 |
#38 | SGRY | United States | $11.50 | $1,145,438,000.00 | Buy | 8 | 2015 |
#39 | KRMD | United States | $4.22 | $41,127,366.00 | Strong Buy | 4 | 2019 |
#40 | AOMR | United States | $7.96 | $0.00 | Strong Buy | 4 | 2019 |
#41 | HCSG | United States | $18.50 | $1,837,173,000.00 | Buy | 6 | 1994 |
#42 | NCMI | United States | $3.03 | $0.00 | Buy | 4 | 2006 |
#43 | IMNM | United States | $19.62 | $6,941,000.00 | Strong Buy | 10 | 2020 |
#44 | CRVS | United States | $14.01 | $0.00 | Strong Buy | 5 | 2016 |
#45 | SDGR | United States | $11.08 | $255,869,000.00 | Buy | 8 | 2020 |
#46 | REAL | United States | $8.57 | $692,845,000.00 | Buy | 8 | 2019 |
#47 | ANNX | United States | $5.01 | $0.00 | Strong Buy | 6 | 2020 |
#48 | SIBN | United States | $12.29 | $67,301,000.00 | Strong Buy | 8 | 2018 |
#49 | IRT | United States | $14.78 | $657,696,000.00 | Buy | 10 | 2009 |
#50 | TARA | United States | $4.94 | $2,948,000.00 | Strong Buy | 6 | 2014 |
The FinQuota filters have identified what they believe to be the "Best Stocks Under $20 to Buy (March 29, 2026) | FinQuota" to buy now. However, please note that this information should not be considered as financial advice, as investing involves risks. We strongly recommend consulting with a qualified financial advisor before making any decisions regarding buying or selling stocks.